Probiotics and their effects in reduction hyperlipidemia (original) (raw)
Related papers
The Effects of Probiotic Supplementation on Dyslipidemia
2017
Introduction Dyslipidemia is a significant yet modifiable risk factor for atherosclerosis and cardiovascular disease (CVD). As CVD is the leading cause of death for men and women in the United States, evaluating novel approaches to risk management is imperative. Standard care for dyslipidemia in those without familial hypercholesterolemia may involve therapeutic lifestyle changes including diet and exercise, as well as pharmacologic management. Despite the efficacy of pharmacologic therapy, not everyone who is suitable for lipid-lowering medications is treated. Barriers to medical treatment may include cost, preference to avoid medication, and statin-induced myalgias.
The Administration of Probiotics against Hypercholesterolemia: A Systematic Review
Applied Sciences
Hypercholesterolemia is a key factor in the progression of atherosclerosis and cardiovascular disease (CVD). CVD is a significant public health concern with a high death rate. Some of the main factors linked to CVD include genetics and lifestyle. Dyslipidemia has been one of the factors related to the onset of several CVD-related diseases. Several clinicopathological studies have shown a correlation between high cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-c), and CVD development. Probiotics have received a lot of attention for various beneficial effects, especially their ability to reduce blood cholesterol in humans. Probiotics were shown in several investigations to affect hypercholesterolemia by influencing cholesterol biosynthesis. The current review focuses on the human dietary interventions with probiotics and their effects on CVD risk factors and hypercholesterolemia. The outcomes are debatable and consider various parameters such as probiotic str...
The Mechanism of Probiotics in Preventing the Risk of Hypercholesterolemia
Reviews in Agricultural Science
Probiotics are beneficial live microorganisms because they provide health benefits to the host after being consumed in sufficient amounts, primarily by increasing the proliferation of native digestive microflora. Hypercholesterolemia is a condition in which cholesterol serum concentration is elevated significantly (exceeds 200 mg/dL). Hypercholesterolemia is characterized by high plasma levels of low-density lipoprotein (LDL) and low plasma concentration of high-density lipoprotein (HDL). This review aims to examine the mechanism of action of probiotics in preventing the risk of hypercholesterolemia and reducing LDL cholesterol levels in the human body. The mechanism of cholesterol-lowering effect of probiotic bacteria can be classified into four basic principles such as 1) the conversion of cholesterol to coprostanol, 2) the deconjugation of cholesterol by probiotics' bile salt hydrolase enzyme, 3) the alteration of protein expression related to cholesterol synthesis, and 4) the production of Short Chain Fatty Acids (SCFA) by probiotics. Cholesterol converted to coprostanol is not absorbed by the small intestine and is directly excreted with the feces. The deconjugated cholesterol is easily precipitated and thus not absorbed by the small intestine. It also induces the assimilation of cholesterol into the probiotic membrane. Finally, the SCFAs, produced by probiotics fermentation within host digestive tract, can upregulate the synthesis of HDL apolipoprotein.
The Hypocholesterolemic Effect of Probiotics in the Hyperlipidemic Hamster
2008
Hypercholesterolemia is a major risk factor for the development of atherosclerosis; a number of pharmacological and non-pharmacological (including dietary) approaches being employed to reduce it. Up until now, the trials to prove the hypocholesterolemic effect of probiotics have not been convincing. There are only few data suggesting that the supplementation of the diet with functional food products containing probiotic bacteria lower LDL-cholesterol (LDL-C) concentration in patients with moderately elevated cholesterol concentration in plasma. The aim of the present study was to evaluate in vivo the anti-atherosclerotic effect of a probiotic compound, containing the Lactobacillus plantarum bacteria, using an animal model of diet induced atherosclerosis, the hyperlipidemic hamster. Results show that this probiotic compound administration to hyperlipidemic hamsters induces: a significant decrease of the total serum cholesterol, a significant increase of the serum antioxidant potentia...
A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics
Scientia Pharmaceutica, 2019
Cardiovascular diseases (CVD) are the major health issue of modernized society with a high mortality rate. Lifestyle, genetic makeup, and diet are some of the major influencing factors associated with CVD. The dyslipidemia is one such factor related to the development of several CVD. Many studies proved that the consumption of probiotics confers several health benefits. Several studies reported the evaluation of the cholesterol-lowering ability of probiotics (probiotics that showed positive effect in vitro and in vivo studies) in human volunteers. The current review summarizes the outcomes of human studies on the cholesterol-lowering property of probiotics. Probiotic consumption significantly improved the health status of hypercholesteremic patients by reducing the low-density lipoprotein cholesterol, total cholesterol, triglyceride levels, and increased the high-density lipoprotein cholesterol. The probiotic supplementation improved the lipid profile of diabetic patients, and obese people as well. However, not all probiotic interventions are effective against dyslipidemia. The results are controversial and depend on several factors such as probiotic strain, dose, duration of the treatment, lifestyle changes, etc. This literature survey indorses additional studies on the cholesterol-lowering property of probiotics, which could help to reduce the risk of CVD and other dyslipidemia associated health issues.
The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol
Systematic reviews, 2018
Dyslipidemia is a major risk factor in triggering cardiovascular events, which can lead to the death of millions of people around the world. Thus, several pharmacological and non-pharmacological therapeutic strategies have been developed in recent decades with the objective of improving lipid profiles, including the use of probiotics. Therefore, the purpose of this protocol is to describe the steps that will guide the construction of an overview to demonstrate the scientific evidence of the efficacy of probiotics in improving the lipid profile of dyslipidemic individuals and to propose specific recommendations regarding their use. The search will be conducted in the following databases: MEDLINE/PubMed, EMBASE, PROSPERO, Cochrane Library, CINAHL, JBI Database of Systematic Reviews and Implementation Reports, Google Scholar, and CADTH. Reviewers will select systematic evaluations and data analyses from randomized clinical trials that evaluated the effects of probiotics on lipid profil...
Probiotics as complementary therapy for hypercholesterolemia
Biology and …, 2009
The role of probiotic organisms as alternative or complementary therapy in combating large number of gastro intestinal disorders and their ability to enhance immune response attracts global attention. In addition, their therapeutic use towards cholesterol-lowering activities has further increased their applications as effective probiotics for humans as supplements in milk and yoghurt, since there are no other supplements for hypercholesterolemia, which is the crucial risk factor for cardiovascular diseases. Changes in dietary habits, stressful life and lack of physical activities are the precursors for increasing incidences of hypercholesterolemia and subsequently cardiovascular diseases. The present review focuses on some of the animal studies and clinical trials conducted with probiotic lactobacilli and bifidobacteria. This review may throw some light to prove the ability of these probiotics as a novel alternative or adjuvants to chemical drugs to help fight hypercholesterolemia.
Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases
Experimental diabetes research, 2012
Cardiovascular diseases are one of the major causes of deaths in adults in the western world. Elevated levels of certain blood lipids have been reported to be the principal cause of cardiovascular disease and other disabilities in developed countries. Several animal and clinical trials have shown a positive association between cholesterol levels and the risks of coronary heart disease. Current dietary strategies for the prevention of cardiovascular disease advocate adherence to low-fat/low-saturated-fat diets. Although there is no doubt that, in experimental conditions, low-fat diets offer an effective means of reducing blood cholesterol concentrations on a population basis, these appear to be less effective, largely due to poor compliance, attributed to low palatability and acceptability of these diets to the consumers. Due to the low consumer compliance, attempts have been made to identify other dietary components that can reduce blood cholesterol levels. Supplementation of diet w...
The aim of the present study was to evaluate and confirm in vivo the cholesterol lowering effect of three commercialized yogurts sold in Buea, a town located in the South West Region of Cameroon. These yogurts are normally known to contain Lactobacillus plantarum and Streptococcus thermophilus bacteria. Following diet induced hyperlipidemia, animal model (wistar albino rats) was used to confirm the persistence of their probiotic cholesterol lowering effect after processing. 42 rats were divided into 7 groups: the positive control group (received hyperlipidemia diet (cholesterol /lard rich diet) + oral gavage of deionized water), the negative control group (fed with basal diet +oral gavage of deionized water), three test groups (fed with hyperlipidemia diet and 3 different types of commercialized yogurt administered orally by gavage respectively), ferment free group (received basal diet + oral administration of yogurt constituents free of ferments (culture)) and hyperlipidemia ferment free group (received hyperlipidemia diet + oral yogurt constituents free of ferments). The oral gavage was daily and the dose volume administered was 1.0 ml/kg body weight. The rats were acclimatized for one week followed by the experimental phase properfor 4 weeks. Daily food consumed and daily weight gains were recorded. At the end of the fourth week, rats were dissected and blood collected for biochemical analysis (total cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, albumin and transaminases activities (ASAT and ALAT)). Organs of the rats (heart, liver, spleen and kidney) were also removed and weighed. Rat growth response revealed no significant change in weight of rats as well as in weights of different organs among test groups meanwhile the weight of these organs and the weight gained by hyperlipidemic group were relatively high compared to test and negative control groups. A slight elevation of ASAT and ALT activities was observed only in Hyperlipidemia rats while the test group did not show any significant increase of these serum enzymes. Results also show that the yogurt administration to hyperlipidemic / hypercholesterolemic rats induced a significant decrease in the total serum cholesterol, VLDL-cholesterol, albumin, LDL-cholesterol and triglycerides, and a significant increase of HDL-cholesterol concentration in sera of test groups. In conclusion, our data support the consumption of potential probiotic yogurt to decrease serum cholesterol and also confirm the persistence of probiotic effects after these yogurts processing techniques. 19 Eurydice Flore Tiepma Ngongang et al.: Effects of Probiotic Bacteria from Yogurt on Enzyme and Serum Cholesterol Levels of Experimentally Induced Hyperlipidemic Wistar Albino Rats